Cargando…

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

BACKGROUND: Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camilio, Ketil A., Wang, Meng-Yu, Mauseth, Brynjar, Waagene, Stein, Kvalheim, Gunnar, Rekdal, Øystein, Sveinbjørnsson, Baldur, Mælandsmo, Gunhild M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343247/ https://www.ncbi.nlm.nih.gov/pubmed/30670061 http://dx.doi.org/10.1186/s13058-018-1092-x

Ejemplares similares

LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014)

The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
por: Mauseth, Brynjar, et al.
Publicado: (2019)

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017)

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma
por: Eike, Liv-Marie, et al.
Publicado: (2016)

Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model
por: Rekdal, Öystein, et al.
Publicado: (2014)

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
por: Camilio, Ketil André, et al.
Publicado: (2014)

The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells
por: Eike, Liv-Marie, et al.
Publicado: (2015)

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
por: Fleten, Karianne Giller, et al.
Publicado: (2021)

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015)

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
por: Yamazaki, Takahiro, et al.
Publicado: (2021)

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
por: Liao, Hsin-Wei, et al.
Publicado: (2019)

The oncolytic peptide LTX-315 triggers immunogenic cell death
por: Zhou, H, et al.
Publicado: (2016)

The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
por: Zhou, Heng, et al.
Publicado: (2015)

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
por: Jebsen, Nina Louise, et al.
Publicado: (2019)

Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer
por: Zhou, Guanhui, et al.
Publicado: (2022)

Understanding the Biophysical Interaction of LTX-315 with Tumoral Model Membranes
por: Klaiss-Luna, Maria C., et al.
Publicado: (2022)

LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
por: Zweytick, Dagmar
Publicado: (2019)

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
por: Tang, Tianyu, et al.
Publicado: (2022)

Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment
por: Santa-González, Gloria A., et al.
Publicado: (2020)

Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge
por: Koo, Dong Jun, et al.
Publicado: (2022)

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
por: Zhou, Heng, et al.
Publicado: (2018)

Novel human melanoma brain metastasis models in athymic nude fox1(nu) mice: Site‐specific metastasis patterns reflecting their clinical origin
por: Svendsen, Henrik A., et al.
Publicado: (2021)

Tetrahydrofurandiols (THF-diols), Leukotoxindiols (LTX-diols), and Endocrine Disruption in Rats
por: Markaverich, Barry M., et al.
Publicado: (2007)

Gangliosides Block Aggregatibacter Actinomycetemcomitans Leukotoxin (LtxA)-Mediated Hemolysis
por: Forman, Michael S., et al.
Publicado: (2010)

Evolution of Indications for Liver Transplantation (LTx) in the Years 2001–2017 in Poland
por: Koczkodaj, Paweł, et al.
Publicado: (2019)

CCL17/TARC and CCR4 expression in Merkel cell carcinoma
por: Rasheed, Kashif, et al.
Publicado: (2018)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

Cancer-Associated Fibroblasts from Lung Tumors Maintain Their Immunosuppressive Abilities after High-Dose Irradiation
por: Gorchs, Laia, et al.
Publicado: (2015)

Aggregatibacter actinomycetemcomitans LtxA Hijacks Endocytic Trafficking Pathways in Human Lymphocytes
por: Lally, Edward T, et al.
Publicado: (2020)

Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA; Leukothera(®)): Mechanisms of Action and Therapeutic Applications
por: Vega, Brian A., et al.
Publicado: (2019)

Sensitization of interferon-γ induced apoptosis in human osteosarcoma cells by extracellular S100A4
por: Pedersen, Kjetil Boye, et al.
Publicado: (2004)

Membrane localization of the Repeats-in-Toxin (RTX) Leukotoxin (LtxA) produced by Aggregatibacter actinomycetemcomitans
por: Brown, Angela C., et al.
Publicado: (2018)

The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation
por: Moens, Ugo, et al.
Publicado: (2013)

Reciprocal transactivation of Merkel cell polyomavirus and high-risk human papillomavirus promoter activities and increased expression of their oncoproteins
por: Rasheed, Kashif, et al.
Publicado: (2021)

Reviewers BJCVS 31.5
Publicado: (2016)

Health Tract No. 315: Presentiments
Publicado: (1868)

A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
por: Wiiger, Merete Thune, et al.
Publicado: (2010)

The Role of Merkel Cell Polyomavirus and Other Human Polyomaviruses in Emerging Hallmarks of Cancer
por: Moens, Ugo, et al.
Publicado: (2015)

T315I-mutated myeloid sarcoma
por: Zhang, Yumeng, et al.
Publicado: (2019)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tkosf4k57p7mnglqvg65amhler